Our understanding of blood production has evolved considerably over the past years, mainly due to the introduction of new technologies to study haematopoietic stem cell (HSC) biology both in situ in their bone marrow (BM) niche and at the clonal level. Recent tracking approaches in native conditions, as opposed to transplantation experiments, have uncovered a prominent role for multipotent progenitors (MPPs) in maintaining blood production 1,2 . Detailed functional studies of the MPP compartment have identified three distinct MPP subsets (MPP2, MPP3 and MPP4) with unique lineage preferences that work together to adjust blood production to the needs of the organism 3,4 . In particular, increased production of myeloid-biased MPP2 and MPP3 by HSCs and myeloid reprogramming of lymphoid-biased MPP4 are now emerging as key first steps of regenerative myelopoiesis 4 .
Imaging GMPs in situ
We took advantage of the phenotypic characteristics of GMPs (Lin − c-Kit + Sca-1 − Fcγ R + CD34 + ) 5 to design an immunofluorescence staining scheme allowing their specific recognition on isolated populations and bone sections (Extended Data Fig. 1a ). In wild-type mice, GMPs were scattered throughout the BM cavity with no particular distribution in relation to the bone endosteum, trabecular regions or central marrow, and were usually identified as individual cells intermingled with other haematopoietic populations ( Fig. 1a ). By contrast, in myeloproliferative neoplasm (MPN) models such as Scl-tTA::TRE-BCR/ABL (BA) 9 and junB flox/flox ::MORE-cre (jB) 10 mice, most GMPs were found as part of large, compact clusters surrounded by lineagepositive cells (Fig. 1b, Extended Data Fig. 1b, c) . This process was progressive and directly associated with disease development, starting with loose GMP patches (pGMP) that evolved into large, compact GMP clusters (cGMP) (Extended Data Fig. 1d ). We defined pGMPs as the collection of more than 4 GMPs loosely associated together, which could also be occasionally observed at steady state in wild-type mice, and distinguished them from cGMPs by the fact that they were not tightly surrounded by mature lineage cells (Extended Data Fig. 1e ). While GMPs were never found in wild-type spleens, we observed abundant cGMPs in the disorganized red pulp of BA and jB mice (Extended Data Fig. 2a ). Similar features were observed in the MLL-AF9 (MF9) transplanted model of acute myeloid leukaemia (AML) 11 , with structures ranging from pGMPs to cGMPs (Extended Data Fig. 2b ). Using a simplified version of this immunofluorescence scheme, we investigated whether cGMP formation was associated with a major re-organization of the BM microenvironment, but found no obvious changes in blood vessel network, hypoxia level, or deposition of extracellular matrix components, except for collagen IV as expected for the fibrotic BA mouse BM niche 12 (Extended Data Fig. 2c ). We also localized mature populations in relation to cGMPs, and although some lymphoid cells were detected inside and at the periphery of cGMPs, myeloid cells were only found tightly surrounding cGMPs (Extended Data Fig. 2d ). These results indicate that leukaemic myelopoiesis is characterized by the presence of cGMPs, which are part of a continuum of differentiation separating progenitors from mature myeloid cells. 
cGMPs are features of myeloid expansion
To determine whether cGMPs could be detected during emergency myelopoiesis, we used several models of myeloid regeneration or active myeloid cell production. First, wild-type mice were injected once with 5-fluorouracil (5-FU; 150 mg kg −1 ) and followed for myeloid regeneration over time ( Fig. 1c ). Flow cytometry analyses showed increased numbers of immature Lin − c-Kit + Sca-1 + (LSK) cells by day 10, which essentially reflected increased production of myeloid-biased MPP2 and MPP3 by 5-FU-activated HSCs (Fig. 1d , Extended Data Fig. 3a, b ). By contrast, GMP numbers were reduced by day 8 and reverted to steady-state levels by day 10, whereas granulocyte numbers sharply decreased by day 8, and then slowly recovered to exceed steady-state levels by day 14. Notably, immunofluorescence staining of 5-FU-treated BM showed rare GMPs at day 8, followed by the appearance of pGMPs by day 8.5, which quickly expanded in size up to day 10 when the first cGMPs were observed ( Fig. 1e , Extended Data Fig. 3c ). By day 12, we only found cGMPs, particularly along the bone endosteum, which then had completely disappeared by day 14 upon granulocyte restoration. We observed similar transient cGMP formation in wild-type mice injected once with Ly-6G antibody (0.1 mg per mouse) to ablate granulocytes specifically 13 , or daily with G-CSF (5 μ g per mouse) to increase granulocyte production 14 (Extended Data Fig. 4a, b ). We also confirmed transient cGMP formation during the peak of myeloid regeneration after HSC transplantation, when both myeloid-biased MPP2/MPP3 and GMPs were specifically expanded 4 (Extended Data Fig. 4c ). Moreover, we demonstrated that cGMPs were predominantly clonal and composed of GMPs derived from individual HSCs undergoing regenerative or leukaemic myelopoiesis (Supplementary Information, Extended Data Fig. 5a-d ). Collectively, these results indicate that transient cGMP formation is a hallmark characteristic of emergency myelopoiesis.
cGMPs are foci of myeloid differentiation
To understand the mechanisms of cGMP formation, we conducted detailed cell cycle analyses by injecting BrdU or EdU into 5-FU-treated wild-type mice ( Fig. 2a , Extended Data Fig. 6a, b ). In LSK cells, BrdU incorporation peaked at day 8 and then progressively reverted to steady-state levels by day 12. In GMPs, BrdU incorporation first increased at day 8, at the onset of pGMP formation, and then dropped below steady-state levels between days 10 and 12 when pGMPs turned into cGMPs, before reverting to steady-state levels by day 14 when cGMPs had disappeared. This pattern was reflected in immunofluorescence staining, with proliferating EdU + pGMPs observed at day 10, and cGMPs markedly devoid of proliferating EdU + cells compared to their surroundings at day 12. By contrast, the number of dividing phospho-histone H3 (pH3)-positive myeloid progenitors was not different between cGMPs and their surroundings at days 10-12, although they appeared preferentially located along the edges of the clusters. Similar analyses performed in BA mice did not uncover altered GMP proliferation rates, and emphasized the preferential distribution of pH3 + dividing cells along the edges of the clusters (Fig. 2b, c) . Close examination of the cGMP periphery in BA mice highlighted a clear differentiation gradient, with reciprocal expression patterns for Fcγ R and lineage markers in GMPs undergoing differentiation across the cluster boundary defined by c-Kit expression ( Fig. 2d ). Singlecell clonogenic methylcellulose analyses of GMPs isolated from 5-FU-treated wild-type mice confirmed a change in differentiation potential associated with cGMP formation, with increased plating efficiency and immature granulocyte/macrophage colonies at days 8-10, followed by restoration of low granulocyte/macrophage frequency and a significant loss of macrophage colonies at days 12-14 ( Fig. 2e ). We also confirmed that mature myeloid cells also directly surrounded cGMPs in 5-FU-treated mice (Extended Data Fig. 6c ). Collectively, these results uncover complex changes in the cellular behaviour of GMPs associated with cluster formation, with increased proliferation and immaturity in expanding pGMPs that form cGMPs, followed by a sharp block in proliferation and restoration of the differentiation potential in differentiating cGMPs that divide to produce mature granulocytes. Moreover, these features of cGMPs as foci of differentiation appear conserved during leukaemic myelopoiesis.
Molecular reprograming in cGMPs
To gain insights into the molecular mechanism controlling cGMP formation, we investigated pools of 100 GMPs isolated from 5-FU-treated wild-type mice using a custom-made Fluidigm quantitative reverse transcription PCR (qRT-PCR) array ( Supplementary  Table 1 ). Principal component and t-distributed stochastic neighbour embedding (tSNE) analyses of the 59 most robustly expressed genes revealed two distinct groups, with day 8 and most day 10 samples (group I) clearly separated from samples from day 0 and days 12-14 (group II) ( Fig. 3a) . Examination of individual genes highlighted signatures of activated cell cycle and strong molecular immaturity in expanding pGMPs (group I), which were completely reverted in differentiating cGMPs (group II) ( Fig. 3b , Extended Data Fig. 7a -c). Similar investigations with leukaemic GMPs revealed a molecular signature of expanding pGMPs in GMPs from both BA and jB mice, with increased Ccne1 expression and decreased levels of Irf8, Csf1r (also known as M-CSFR) and Il6ra (Fig. 3c , Extended Data Fig. 7d , Supplementary Table 2 ). To investigate global transcriptional changes, we also performed single-cell RNA-seq on GMPs isolated from 5-FU-treated wild-type mice, and BA and age-matched control mice. Principal component analysis and hierarchical clustering of all single GMPs also displayed two major clusters ( Fig. 3d , Extended Data Fig. 7e , Supplementary Tables 3 and 4 ). Remarkably, day 0 and control GMPs showed high expression of the previously defined group II genes and reflected steady-state GMPs, whereas day 8 5-FU-treated and BA GMPs were characterized by expression of group II genes and coincided with self-renewing GMPs. Allocation to each cluster of all single GMPs across the 5-FU kinetics and in BA mice showed the presence of 8.5-13.5% self-renewing GMPs at the steady state, and persistence of around 15% of steady-state GMPs at day 8 and the peak of selfrenewing pGMPs ( Fig. 3e ). Together, these results uncover considerable molecular reprogramming during cGMP formation, characterized by cell cycle activation and suppression of maturation pathways in expanding pGMPs, followed by cell cycle blockade and re-activation of maturation pathways in differentiating cGMPs. They also indicate that leukaemic GMPs are molecularly primed for cGMP formation. Moreover, they demonstrate the co-existence of distinct steady-state and self-renewing GMPs in both normal and leukaemic contexts, in proportions that reflect the activation state of emergency myelopoiesis.
GMP self-renewal network
We next probed the function of the key myeloid transcription factor Irf8 (ref. 15 ) in cGMP formation. Irf8 −/− mice are immunodeficient and develop MPN over time 16 . Similar to BA and jB mice, we observed constitutive cGMP formation in the BM of primary or transplanted Irf8 −/− mice ( Fig. 4a , Extended Data Fig. 8a -c), thus demonstrating that decreasing Irf8 expression is sufficient to drive cGMP formation. We also found delayed cGMP formation in 5-FU-treated primary and transplanted Irf8 −/− mice, which, in turn, indicates that restoration of Irf8 expression is essential for cGMP differentiation, probably by increasing expression of genes such as Csf1r, a direct Irf8 target 17 . Notably, Irf8 and Ctnnb1 (encoding β -catenin) are part of an antagonistic regulatory network in chronic myeloid leukaemia (CML) 18 , and activated β -catenin signalling provides aberrant self-renewal features to leukaemic GMPs in both CML and AML 19, 20 . Notably, we observed increased levels of nuclear β -catenin in day 8 regenerating GMPs, and in GMPs from both BA and jB mice (Fig. 4b, c ). However, downregulation of Irf8 did not directly drive β -catenin as neither Irf8 −/− GMPs nor HSCs or MPPs showed increased nuclear β -catenin ( Fig. 4d , Extended Data Fig. 8d ). By contrast, GMPs from Ctnnb1 gain-of-function (GOF) and loss-of-function (LOF) mice had decreased and increased Irf8 expression, respectively, leading to the presence of pGMPs at the steady state in Ctnnb1 GOF mice, and unchanged steady-state levels but delayed cGMP formation after 5-FU treatment in Ctnnb1 LOF mice ( Fig. 4e -g, Extended Data Fig. 8e , f). Collectively, these results place Irf8 and β -catenin at the centre of an inducible self-renewal progenitor network controlling cGMP formation, with β -catenin directly suppressing Irf8 expression and Irf8 eventually re-enforcing β -catenin expression in MPN contexts ( Fig. 4h ).
BM niche signals control cGMP formation
To identify the environmental factors involved in cGMP formation, we performed ELISA analyses on BM fluid from 5-FU-treated wildtype mice (Fig. 5a ). Notably, we found significantly increased levels of cytokines known to stimulate HSC proliferation and trigger myeloid differentiation, such as SCF, G-CSF and IL-1, before pGMP expansion (days 5-8), and factors important for restoring HSC quiescence, such as TGFβ 1 and CXCL4 (also known as PF4), at the time of cGMP formation (days 10-12) 21 . By contrast, we observed no change in the BM homing chemokine CXCL12 (also known as SDF1α ), and a decrease rather than the reported increase 22 in FGF1 production (Extended Data Fig. 9a ). G-CSF and IL-1 are both produced by the damaged vasculature in stress conditions 13, 23 . Immunofluorescence staining confirmed notable vascular damage after 5-FU treatment, with major gaps between dysmorphic laminin + endothelial cells leading to vascular leakage into the stromal microenvironment, especially at days 8-10 when pGMPs expand ( Fig. 5b, Extended Data Fig. 9b ). To probe the role of G-CSF directly, we injected it for 4 consecutive days in 5-FU-treated wild-type mice either from days 1 to 4 (early injections) before pGMP expansion, or from days 8 to 11 (late injections) during the cGMP differentiation period (Fig. 5c, Extended Data Fig. 9c ). Notably, early G-CSF injections markedly accelerated cGMP formation, whereas late G-CSF injections considerably amplified and extended the period of cGMP formation. In addition, we recently reported impaired myeloid regeneration in 5-FU-treated Il1r1 −/− mice, and showed that IL-1 triggers regenerative myelopoiesis by activating PU.1 in HSCs 23 . Consistently, we observed markedly delayed cGMP formation in 5-FU-treated Il1r1 −/− mice, and constitutive cGMP formation at the steady state in IL-1-treated wildtype mice (Fig. 5d , Extended Data Fig. 9d ).
TGFβ 1 and CXCL4 are both produced by megakaryocytes, which are important components of the HSC niche 24, 25 . Immunofluorescence staining showed an overabundance of large, mature CD150 + megakaryocytes in close association with cGMPs in every tested regenerative context, including 5-FU, G-CSF and Ly-6G treatments (Fig. 5e, Extended Data Fig. 9e ). To address the role of megakaryocytes in secreting quiescence-enforcing signals, we used a previously published diphtheria-toxin-based approach to deplete megakaryocytes in 5-FU-treated Cxcl4-cre::iDtr mice 24 (Fig. 5f , Extended Data Fig. 9f ). Remarkably, megakaryocytes depletion caused persisting cGMP formation during the granulocyte outburst period, a massive reduction in CXCL4 and TGFβ 1 production, and prevention of HSC return to quiescence ( Fig. 5f -h, Extended Data Fig. 9g ). Collectively, these findings demonstrate that many distinct and temporally regulated BM niche signals are important for various aspects of cGMP formation (Fig. 6a ). This includes the early production of SCF and IL-1, which activate HSCs to produce MPP2/MPP3 and initiate emergency myelopoiesis, the release of G-CSF, which dictates when self-renewing pGMPs are formed, probably by triggering the Irf8 and β -catenin progenitor self-renewal network, and the late production of TGFβ 1 and CXCL4 by megakaryocytes surrounding cGMPs, which re-establish HSC quiescence and limit the duration of the regenerative response.
Deregulated cGMP formation in leukaemia
To understand why cGMP formation is constitutively activated in leukaemia, we performed similar ELISA analyses on BM fluid from BA and jB mice (Fig. 6b, Extended Data Fig. 10a ). Notably, we found a consistent decrease in quiescence-enforcing cytokines in both MPN models, with undetectable levels of TGFβ 1 and CXCL4 in BA mice, and significantly reduced TGFβ 1 production in jB mice. Immunofluorescence staining revealed decreased numbers of CD150 + megakaryocytes in close proximity of cGMPs in both MPN models, ranging from almost absent in BA mice to infrequent in jB mice (Fig. 6c ). qRT-PCR analyses further confirmed reduced Cxcl4 (also known as Pf4) expression from BA megakaryocytes (Extended Data Fig. 10b ). Moreover, immunofluorescence of laminin + blood vessels indicated constitutively damaged endothelial cells with high vascular leakage in both MPN models (Fig. 6c, Extended Data Fig. 10c ). We also observed persistence of very large cGMPs associated with constant granulocyte overproduction in 5-FU-treated BA mice (Fig. 6d , Extended Data Fig. 10d ). These results indicate that transformed HSC-derived leukaemic stem cells continuously produce cGMPs as a direct consequence of high levels of activating cytokines, such as IL-1, produced by the inflamed leukaemic BM niche 12 . This, in turn, results in the overproduction of MPP2 and MPP3 (ref. 9) , which are committed to form pGMPs probably because of to the constitutive activation of the progenitor self-renewal Irf8 and β -catenin network by the driving oncogenes, rather than by extrinsic myeloid cytokines. Most importantly, this activation process never stops because essential quiescence-enforcing cytokines such as TGFβ 1 and CXCL4 are missing owing to the loss or insufficient production of leukaemic megakaryocytes. Altogether, these results demonstrate that the leukaemic BM niche is both constitutively activated and lacking important feedback mechanisms, thereby driving constant cGMP formation and granulocyte production ( Fig. 6e ).
Discussion
Our results expand the understanding of myeloid progenitor biology, and report a new and highly dynamic in situ behaviour of GMPs that link changes in their molecular and cellular functions with spatial organization in the BM niche. We identify two functional states for GMPs, with self-renewing pGMPs building GMP clusters, and differentiating cGMPs producing mature myeloid cells until the complete disappearance of the GMP clusters. This biphasic process is a transient feature of emergency myelopoiesis, and is highly controlled by the timed released of various BM niche signals. These findings, together with the recent identification of myeloid-biased MPP2 and MPP3 (ref. 4 ), help to construct a revised map of emergency myelopoiesis pathways and a deeper understanding of their hijacking in leukaemia (Extended Data Fig. 10e ). They also provide an explanation for the recently reported molecular heterogeneity in GMPs 6, 7, 26 , with the co-existence in variable proportions of distinct steady-state and self-renewing GMPs, and are essential for interpreting the results of lineage-tracking experiments showing major contributions of MPPs and myeloid progenitors to myeloid output 1,2 . Moreover, they equate cGMP formation with regulated myelopoiesis, and identify several mechanisms that could be harnessed for translational applications. Pathological investigations have reported the presence of immature myeloid cell aggregates in the bones of patients with leukaemia 27 , including clusters of proliferating myeloblasts surrounded by TGFβ 1producing megakaryocytes 28 , which could represent similar cGMP formation in humans. Future studies will address whether targeting various regulators of cGMP formation can be used to prevent the development of myeloid malignancies or, conversely, to boost myeloid cell production in myelosuppressed conditions. Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Article reSeArcH MethOdS Mice. Six-to twelve-week-old C57Bl/6-CD45.2 wild-type mice were used as donor for cell isolation and in vivo treatments. Eight-to twelve-week old C57Bl/6-CD45.1 (Boy/J) wild-type mice were used as recipients for cell transplantation experiments. C57Bl/6-CD45.2 Scl-tTA::TRE-BCR/ABL (BA) 9 , junB flox/flox ::MORE-Cre (jB) 10 , Irf8 −/− 16 , Il1r1 −/− 29 , Csf1r-Gfp 30 , Actb-Gfp 31 , Ctnnb1 Flox(Ex3) (GOF) 32 , Ctnnb1 flox/flox (LOF) 33 , Mx1-cre 34 , Cxcl4-cre 35 and iDtr 36 mice were used for bone collection and in vivo treatments at various ages. Bones from control and MLL-AF9 transplanted mice 11 shipped overnight from S.A. 's laboratory were immediately used upon delivery. BA mice were bred in the presence of 20 mg l −1 doxycycline (Sigma-Aldrich, D9891-10G) in their drinking water, and induced for CMLlike MPN development by doxycycline withdrawal at 5 weeks of age. Recipient mice were irradiated at a lethal dose of 11 Gy delivered in split doses 3 h apart using a 137 Cs source (J. L. Shepherd). BM cells were injected in a volume of 100 μ l into the retro-orbital plexus immediately after irradiation, and transplanted mice were treated with antibiotics for 4 weeks post-irradiation. Peripheral blood was obtained from retro-orbital bleeding, and either collected in tubes containing 4 ml of ACK (150 mM NH 4 Cl and 10 mM KHCO 3 ) and 10 mM EDTA for flow cytometry analyses, or in EDTA-coated microtainer tubes (Beckton-Dickenson) for complete blood counts using an Hemavet hematology system (Drew Scientific). BM cellularity was determined using a ViCell automated cell counter (Beckman-Coulter). For 5-FU treatments, mice were injected intraperitoneally (i.p.) once with 150 mg kg −1 5-FU (Sigma-Aldrich, F6627-5G) or PBS control. All 5-FU-injected mice were screened for efficient myeloablation by complete blood count analyses and BM cellularity measurement. For Ly-6G treatment, mice were injected i.p. once with 0.1 mg of anti-Ly-6G or rat-IgG control antibodies (UCSF Hybridoma Core Facility). For G-CSF treatments, mice received daily i.p. injections of 5 μ g G-CSF (Neupogen) or PBS control. For Mx1-cre-mediated deletion, mice were injected i.p. three times 2 days apart with 250 μ g of poly(I/C) (pIC, GE Healthcare) in 200 μ l PBS. For IL-1β treatments, mice received daily i.p. injections of 0.5 μ g IL-1β (Peprotech) or PBS/0.2% BSA control. For megakaryocyte depletion, mice received daily i.p. injections of 250 ng diphtheria toxin (List Biological Laboratories, 150) or PBS control. Megakaryocytes depletion was confirmed by complete blood count analyses and immunofluorescence staining. For proliferation analyses, mice were injected once i.p. with either BrdU (Sigma-Aldrich, B5002-5G) or EdU (Thermo Fisher Scientific, A00144) 1 h before euthanization. For pimonidazol staining, mice were injected with 60 mg kg −1 pimonidazole-HCl (Hypoxyprobe, HP2-100Kit) and euthanized 1 h later. For investigations of vascular integrity, mice were injected with 50 μ l of dragon green (DG) beads (Bangs Laboratories, FS02F/10597) 10 min before euthanization, and immediately perfused with 10 ml PBS by cardiac puncture before bone collection as described 37 . No specific randomization or blinding protocol was used, mice of both genders were used, and all experiments were performed in accordance with UCSF IACUC approved protocols. Flow cytometry. BM stem and progenitor populations were analysed and/ or isolated as previously described 4 . In brief, BM cells were obtained by either crushing leg, arm and pelvic bones or just flushing leg bones in HBSS containing 2% heat-inactivated FBS (Sigma-Aldrich). HBSS/2% FBS was used for all incubation and wash steps. Erythrocytes and contaminating bone material were removed by ACK lysis followed by centrifugation on a Ficoll gradient (Histopaque 1119, Sigma-Aldrich) for crushed bones. For cell analyses, unfractionated BM cells were incubated with purified, unconjugated-lineage antibodies (CD3 from Biolegend, and CD4, CD5, CD8, B220, Ter119, Mac-1 and Gr-1 from eBioscience) followed by goat anti-rat-PE-Cy5 (Invitrogen, A10691) and subsequently blocked with purified rat IgG (Sigma-Aldrich, I8015-10MG). Cells were then stained with c-Kit-APC-eFluor780 (eBioscience, 47-1171-82), Sca-1-PB (BioLegend, 108120), CD48-A647 (BioLegend, 103416), CD150-PE (BioLegend, 115904) and either CD34-FITC (eBioscience, 11-0341-85) together with Fcγ R-PerCP-eFluor710 (eBioscience, 46-0161-82) for combined stem/progenitor staining or only ESAM-FITC (Biolegend, 136205) for detailed analyses of HSC and MPP2/3 after 5-FU treatment. For Csf1r-Gfp mice, CD34-FITC was replaced by CD34-Bio (Biolegend, 119304) followed by staining with SA-PeCy7 (eBioscience, 25-4317-82). For GMP sorting, BM cells were first pre-enriched for c-Kit + cells using c-Kit microbeads (Miltenyi Biotec, 130-091-224) and MACS Separation LS Columns (Miltenyi Biotec, 130-042-401), and stained as described with Lin-PE-Cy5, c-Kit-APC-eFluor780, Sca-1-PB, CD34-FITC and Fcγ R-PerCP-eFluor710. For mature cell analyses, unfractionated BM cells were stained with Mac-1-PE-Cy7 (eBioscience, 25-0112-82), Gr-1-PB (eBioscience, 57-5931-82), B220-APC-Cy7 (eBioscience, 47-0452-82) and CD19-PE (eBioscience, 12-0193-82). Peripheral blood cells were stained with Mac-1-PE-Cy7, Gr-1-PB, B220-APC-Cy7, CD3-APC (eBioscience, 17-0032-82) and Ter119-PE-Cy5 (eBioscience, 15-5921-83), with either co-detection of GFP or addition of CD45.1-FITC (eBioscience, 11-0454-85) and CD45.2-PE (eBioscience, 12-0453) for analyses of chimaeric mice. Stained cells were finally re-suspended in HBSS/2% FBS containing 1 μ g ml −1 propidium iodide for dead cell exclusion, and either sorted on a FACS ARIAII or analysed on a LSRII using DIVA software (Becton Dickinson). GMPs were double sorted to ensure maximum purity. For intracellular BrdU and Ki67/ DAPI staining, BM cells were first stained as above, then fixed in Cytofix/Cytoperm buffer (BD Biosciences, 554714) for 10 min (BrdU) or 30 min (Ki67/DAPI) in the dark, washed in PermWash (BD Biosciences), permeabilized with CytoPerm Plus (BD Biosciences) for 10 min at room temperature, re-fixed in Cytofix/Cytoperm buffer for 5 min in the dark and washed in PermWash. For BrdU staining, cells were then treated with 0.5 U μ l −1 DNaseI in 3% BSA, 0.2× PBS, 5 mM MgCl 2 and 2 mM CaCl 2 for 30 min at room temperature in the dark, washed in PermWash, stained with FITC-conjugated anti-BrdU (347583, BD Biosciences) for 30 min at room temperature, washed in PermWash, and re-suspended in HBSS/2% FBS. For Ki67/DAPI staining, cells were then stained with anti-Ki67 antibody (eBioscience, 11-5698-80) for 1 h at room temperature in the dark, washed in PermWash and re-suspended in HBSS/2% FBS containing DAPI at 1 μ g ml −1 (Sigma-Aldrich, 32670). In both cases, cells were analysed on a FACS LSR II as described above. Immunofluorescence on tissue sections. Mouse femurs or spleens were snap frozen in OCT (Tissue-Tek) and kept at − 80 °C until sectioning. Frozen samples were cryosectioned (7 μ m) using a Cryostat equipped with the Cryojane tape transfer system and tungsten blades (Leica Microsystems). Sections were dried for 2-4 h at room temperature and then frozen at − 80 °C until stained. Before staining, sections were fixed with 100% acetone for 10 min at − 20 °C, dried for 5 min at room temperature and blocked for 1 h 30 min with 10% goat-serum (Gibco) in PBS. For regular GMP staining, sections were incubated first with rat anti-mouse c-Kit (Biolegend, 135102) primary antibody overnight at 4 °C in PBS/10% goatserum, followed with a goat anti-rat-Cy3 (Jackson Immunoresearch, 112-165-167) secondary antibody for 1 h at room temperature in PBS/10% goat-serum and washed three times for 5 min with PBS at room temperature. These wash steps were also performed between each staining steps. Sections were then blocked with 20 μ g ml −1 Rat IgG (Sigma-Aldrich, I8015-10MG) for 10 min at room temperature in PBS, and finally stained with A488-conjugated lineage markers (B220 from Invitrogen, and Mac-1, Gr-1 and CD3 from Biolegend), Sca-1-A488 (Biolegend, 108116), CD150-A488 (Biolegend, 115916) and Fcγ R-A647 (UCSF Hybridoma Core Facility) for 1 h 30 min at room temperaturein PBS/10% goatserum. For GMP staining of the MLL-AF9 transplantation model, the eBioscience mouse haematopoietic lineage biotin panel (88-7774), Sca-1-bio (eBioscience, 13-5981-1630), and CD150-bio (Biolegend, 115908) were used instead of A488conjugated antibodies, followed by staining with a SA-e450 (eBioscience, 48-4317) antibody. For laminin and GMP co-staining, Fcγ R was omitted and rabbit antimouse laminin (Sigma-Aldrich, L9393) followed by staining with a goat antirabbit-A647 secondary antibody was used instead. For the other GMP co-staining, A647-conjugated lineage antibodies (Biolegend, B220, Mac-1, Gr-1 and CD3), Sca-1-A647 (Biolegend, 108118) and CD150-A647 (Biolegend, 115918) were used instead of A488-conjugated antibodies, and Fcγ R was omitted. For laminin and extracellular matrix protein co-detection, rabbit anti-mouse laminin, Collagen IV (Abcam, ab6586) and fibronectin (Abcam, ab23750) were used followed by staining with a donkey anti-rabbit-A488 (Sigma-Aldrich, A-21206) secondary antibody. For clonality analyses, either CD45.2-FITC (Biolegend, 109816) or A488-conjugated anti-GFP (Aves labs, GFP-1020) were used. For laminin and DG-bead co-staining, sections were just stained with rabbit anti-mouse laminin followed by goat antirabbit-A647. For proliferation analyses, either pH3-FITC (Cell Signaling, 9708S) or Click-iT EdU Alexa Fluor 488 Imaging Kit (ThermoFisher Scientific, C10337) were used according to the manufacturer's instructions. For myeloid/lymphoid cells and GMP co-staining, Fcγ R, CD150 and Sca-1 were omitted and B220-A488 (Invitrogen, RM2620), CD3-A488 (Biolegend, 100210), Gr-1-A647 (Biolegend, 108418) and Mac-1-A647 (Biolegend, 101218) were used instead. For megakaryocytes and GMP co-staining, Fcγ R was omitted and rat anti-mouse CD150 (Biolegend, 115902) followed by staining with a goat anti-rat-Cy3 secondary antibody was used instead. For cleaved caspase 3 (CC3) and GMP co-staining, Fcγ R was omitted and sections were fixed for 10 min with 4% PFA at room temperature then washed three times for 5 min at room temperature in PBS/0.1% Triton X-100. Sections were first incubated with a rabbit anti-CC3 (Cell Signaling, 9661-S) antibody followed by a goat anti-rabbit-A647 (Thermo Fisher Scientific, A-21245) secondary antibody, and then stained as usual for c-Kit and A488-conjugated lineage. For pimonidazol staining, frozen sections were fixed with 4% PFA for 10 min at room temperature and stained with FITC-conjugated anti-pimonidazole (Hypoxyprobe, HP2-100Kit) according to the manufacturer's instructions. After staining, all sections were counterstained with 1 μ g ml −1 DAPI in PBS for 10 min at room temperature, mounted with fluoromount (Southern Biotech, 0100-01) and imaged on SP5 upright or SP8 inverted confocal microscopes (Leica) with a 20× objective. Images were processed using Volocity software (Perkin Elmer v.6.2) and
Article reSeArcH analysed with ImageJ. The analyse particle function and a threshold mask covering laminin + cells was also used in ImageJ to quantify dragon-green bead mean fluorescence intensity outside of blood vessels. Immunofluorescence on purified cells. GMP (2,000 cells per slide) were directly sorted onto poly-lysine coated slides (Sigma-Aldrich, P0425-72EA) and allowed to settle for 15 min. Cells were washed three times for 5 min with PBS between each staining step. For GMP re-stain, cells were fixed with 100% acetone for 5 min at − 20 °C, blocked for 1 h 30 min at room temperature with PBS/10% goat serum and stained as described above for regular GMP staining on sections. For β -catenin staining, cells were fixed with 4% PFA for 10 min at room temperature, and then permeabilized and blocked with PBS/0.1% Tween-20/10% FBS for 1 h. Cells were then stained with a rabbit anti-mouse β -catenin (Cell Signaling, 9582S) primary antibody overnight at 4 °C in PBS/0.1% Tween-20/10% FBS, followed by an anti-rabbit-A555 (Invitrogen, A31572) secondary antibody for 1 h at room temperature in PBS/0.1% Tween-20/10% FBS. Slides were mounted with VectaShield (Vector Laboratories, H-1200) containing 1 μ g ml −1 DAPI and imaged on a SP5 upright confocal microscope (Leica) with a 20× objective. Images were processed using Volocity software and an average of 390 individual cells were scored per condition for nuclear β -catenin quantification. In vitro analyses. All cultures were performed at 37 °C in a 5% CO 2 water jacket incubator (Thermo Scientific). For clonogenic methylcellulose colony assays, GMPs (1 cell per well) were directly sorted into 96-well plates containing 100 μ l methylcellulose (Stem Cell Technologies, M3231) supplemented with the following cytokines (all from PeproTech): IL-3 (10 ng ml −1 ), GM-CSF (10 ng ml −1 ), SCF (10 ng ml −1 ), IL-11 (10 ng ml −1 ), Flt-3L (10 ng ml −1 ), Tpo (100 ng ml −1 ) and Epo (4 U ml −1 ). Colonies were visually scored after 7 days of culture. Fluidigm analyses. Gene expression analyses using the Fluidigm 96.96 Dynamic Array IFC were performed as previously described 4 . Briefly, GMPs (100 cells per well) were directly sorted into 96 well-plates containing CellsDirect lysis buffer (Invitrogen, 11753-100), reverse-transcribed and pre-amplified for 18 cycles using Superscript III Platinum Taq DNA polymerase (Invitrogen, 18080-044) using a custom-made set of 96 proprietary target-specific primers (Fluidigm). The resulting cDNAs were analysed on a Biomark system (Fluidigm) using EvaGreen Sybr dye (Bio-Rad, 172-5211). Data were collected using Biomark Data Collection Software (Fluidigm) and analysed using Biomark qPCR analysis software with a quality threshold of 0.65 and linear baseline correction. Identical settings were used across all experiments performed on different 96.96 dynamic arrays. Melt curves and T m values for each assay reaction were checked individually, and reactions with melt curves showing multiple peaks or poor quality (< 0.65) were discarded, leaving 60 genes and 2 housekeeping genes (Gusb and Gapdh) for further analyses. For gene expression quantification, data were exported as an Excel.csv file and analysed by the Δ Δ C t method using Gusb (5-FU GMPs) or Gapdh (MPN GMPs) for normalization. tSNE and principal component analyses were performed as previously described 4 on the 59 (5-FU GMPs) and 35 (MPN GMPs) most robustly expressed genes following quality control assessment, and normalized to Gapdh. Single-cell RNA-seq. Single GMPs were directly sorted into individual wells of a 96-well PCR plate containing 2.3 μ l of 0.2% Triton X-100 (Sigma-Aldrich, 93443) and 2.3 U of SUPERase-In RNase Inhibitor (Ambion, AM2694). cDNA was obtained and amplified following the described SMARTSEQ2 protocol 38 . Libraries were prepared for sequencing from 125 ng of cDNA using the Illumina Nextera XT DNA preparation kit. Pooled libraries were run on the Illumina HiSeq 2500 (5-FU samples) or Illumina HiSeq 4000 (BA samples). Reads were mapped to the Mus musculus genome (Ensembl GRCm38.81) and the ERCC sequences using GSNAP (version 2015-09-29) with -B 5 (batch mode 5) -n 1 (maximum pathsallowed: 1) -Q (if maximum paths more than n, not print) -N 1 (look for novel splicing). HTseq-count was used to count the number of reads mapped to each gene with -s no (non-strand specific mode) 39 . For further analyses, we only retained samples that had (1) more than 100,000 reads mapped to nuclear mRNAs;
(2) more than 4,000 highly detectable genes (defined as genes with more than 10 reads per million); and (3) less than 20% of mapped reads allocated to mitochondrial genes. The data were normalized for sequencing depth using the package scran from R Bioconductor. Highly variable genes were identified as described 40 , using a false discovery rate threshold equal to 0.1. Only highly variable genes were considered to perform principal component analysis, using the prcomp command in R. Hierarchical clustering was performed using highly variable genes to identify ssGMPs and srGMPs. The pairwise Spearman correlation coefficients (ρ) were calculated between the expression levels of highly variable genes in each pair of cells. The dissimilarity matrix was then calculated as (1 − ρ)/2. Hierarchical clustering was performed using the default 'complete' method on the dissimilarity matrix. Identification of cells contained in each of the two clusters (corresponding to ssGMPs and srGMPs) was done using the cutree method with k = 2 (2 groups). Genes differentially expressed (DE) between ssGMP and srGMP clusters were identified using DESeq2 (version 1.12.2) 41 and only DE genes having a fold change significantly greater than 1.5 with a false discovery rate threshold less than 0.1 were used for hierarchical clustering. qRT-PCR. For megakaryocytes enrichment, flushed BM cells were filtered through a 100-μ m mesh filter and sedimented 30 min at room temperature through a gradient of 1.5 to 3% BSA, with megakaryocytes pelleting at the bottom of the 3% BSA gradient. Total RNA was isolated from 3 × 10 4 cells re-suspended in Trizol LS (Life Technologies, 10296-010) according to the manufacturer's protocol. For qRT-PCR, RNA was treated with DNaseI and reverse-transcribed using SuperScript III kit and random hexamers (Life Technologies, 18080-051). Runs were performed on a 7900HT Fast Real-Time PCR system (Applied Biosystems) using SybrGreen reagents (Kapa Biosystems, KK4603) and the cDNA equivalent of 200 cells per reaction. Sequences for qRT-PCR primers were: Cxcl4 sense 5′ -TCTCCTCTGGGATCCATCTT-3′ , Cxcl4 antisense 5′ -CATTCTTCAGGGTGGCTATGA-3′ (NM_019932); Αctb sense 5′ -GACGGCCAGGTCATCACTATTG-3′ , Actb antisense 5′ -AGGAAGGCTGGAAAAGAGCC-3′ (NM_007393). Values were normalized to Actb expression levels. Cytokine ELISA. For collecting BM fluids, the four long bones (two femurs and two tibiae) of each mouse were flushed with the same 200 μ l of HBSS/2% FBS using a 0.3cc insulin syringe with a 28g needle and spun at 500g for 5 min to remove BM cells. Supernatants were further clarified by spinning down at 12,000g for 10 min, and samples were subsequently stored at − 80 °C until use. For ELISA measurements, 4× -diluted (SCF, CXCL12, FGF1), 5× -diluted (TGFβ 1), 20× -diluted (G-CSF) and 1,000× -diluted (CXCL4) samples were analysed according to the manufacturer's instructions (Raybiotech for SCF, G-CSF, CXCL4 and CXCL12; R&D Systems for TGFβ 1) or as previously described for FGF1 (ref. 22) . Statistics. All experiments were repeated as indicated. n indicates the numbers of independent biological repeats. The numbers of independent experiments are reported in the Supplementary Information. For immunofluorescence images, representative examples of at least two independent experiments are shown. Data are expressed as means ± s.d. unless otherwise indicated. Statistical analyses were performed using Prism 5.0 software (GraphPad). Pairwise statistical significance was evaluated by Student's t-test. Mice for treatment and transplantation were randomized, and no blinding protocol was used. No statistical method was used to predetermine sample size. P ≤ 0.05 was considered statistically significant. Data availability. Datasets that support the findings of this study have been deposited online with the Gene Expression Omnibus (GEO) under accession number GSE90799. Source Data for all the figures are provided with the paper. All other data are available from the corresponding author upon reasonable request. 

